Heval Atas Guvenilir

Heval Atas Guvenilir

Auto-generated profile, based on publicly available information

Heval Atas Guvenilir

Department of Bioinformatics, Fraunhofer Institute for Algorithms and Scientific Computing (SCAI), Sankt Augustin, Germany

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2022 in Nature Machine Intelligence
Verified
Journal Article
Closed access
PDF file
SUSerbulent Unsal
Serbulent Unsal
HAHeval Atas
Heval Atas
MAMuammer Albayrak
Muammer Albayrak
KTKemal Turhan
Kemal Turhan
AAAybar C. Acar
Aybar C. Acar
TDTunca Doğan
Tunca Doğan

29 November 2021 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
TDTunca Doğan
Tunca Doğan
EGEce Akhan Güzelcan
Ece Akhan Güzelcan
Marcus BaumannMarcus Baumann
Marcus Baumann
AKAltay Koyas
Altay Koyas
HAHeval Atas
Heval Atas
RCRengul Cetin-Atalay
Rengul Cetin-Atalay
Predictive approaches such as virtual screening have been used in drug discovery with the objective of reducing developmental time and costs. Current machine learning and network-based approaches have issues related to generalization, usability, or model interpretability, especially due to the complexity of target proteins’ structure/function, and bias in system training datasets. Here, we propose a new method “DRUIDom” (DRUg Interacting Domain prediction) to identify bio-interactions between drug candidate compounds and targets by utilizing the domain modularity of proteins, to overcome problems associated with current approaches. DRUIDom is composed of two methodological steps. First, ligands/compounds are statistically mapped to structural domains of their target proteins, with the aim of identifying their interactions. As such, other proteins containing the same mapped domain or domain pair become new candidate targets for the corresponding compounds. Next, a million-scale dataset of small molecule compounds, including those mapped to domains in the previous step, are clustered based on their molecular similarities, and their domain associations are propagated to other compounds within the same clusters. Experimentally verified bioactivity data points, obtained from public databases, are meticulously filtered to construct datasets of active/interacting and inactive/non-interacting drug/compound–target pairs (~2.9M data points), and used as training data for calculating parameters of compound–domain mappings, which led to 27,032 high-confidence associations between 250 domains and 8,165 compounds, and a finalized output of ~5 million new compound–protein interactions. DRUIDom is experimentally validated by syntheses and bioactivity analyses of compounds predicted to target LIM-kinase proteins, which play critical roles in the regulation of cell motility, cell cycle progression, and differentiation through actin filament dynamics. We showed that LIMK-inhibitor-2 and its derivatives significantly block the cancer cell migration through inhibition of LIMK phosphorylation and the downstream protein cofilin. One of the derivative compounds (LIMKi-2d) was identified as a promising candidate due to its action on resistant Mahlavu liver cancer cells. The results demonstrated that DRUIDom can be exploited to identify drug candidate compounds for intended targets and to predict new target proteins based on the defined compound–domain relationships. Datasets, results, and the source code of DRUIDom are fully-available at:https://github.com/cansyl/DRUIDom.

5 November 2026 in Knowledge-Based Systems
Verified
Journal Article
Closed access
AMAhmed Hossameldin Mohamed
Ahmed Hossameldin Mohamed
KSKarim S Shalaby
Karim S Shalaby
AKAbish Kaladharan
Abish Kaladharan
SSSutrishna Sen
Sutrishna Sen
HGHeval Atas Güvenilir
Heval Atas Güvenilir
AKAlpha Tom Kodamullil
Alpha Tom Kodamullil

19 August 2025 in bioRxiv
Verified
Preprint
Open access
HGHeval Atas Guvenilir
Heval Atas Guvenilir
PSPriya Sethumadhavan
Priya Sethumadhavan
AKAbish Kaladharan
Abish Kaladharan
RSRenata Vieira de Sa
Renata Vieira de Sa
ASAdithya Sridhar
Adithya Sridhar
AKAlpha Tom Kodamullil
Alpha Tom Kodamullil
Summary: COVID-19 is increasingly recognized as a potential trigger or accelerator of neurodegenerative diseases such as Alzheimer’s and Parkinson’s. To systematically explore the putative molecular and clinical associations between them, we present CBM KG (Causal Biological Mechanisms Knowledge Graph)—a manually curated, comorbidity-centric resource developed within the EU-funded COMMUTE project. CBM KG integrates over 2,800 cause-and-effect or correlative relationships from 63 peer-reviewed publications, highlighting key mechanisms such as viral entry routes, blood-brain barrier alteration, microglial activation, neuroinflammation, and APOE ε4-associated susceptibility. Each relationship in the graph is fully traceable to its source evidence, ensuring transparency and reproducibility. Unlike general-purpose or single disease-focused knowledge graphs, CBM KG is specifically designed to represent causal biological mechanisms spanning both infectious and neurodegenerative processes. By encoding directional, cause-and-effect relationships, it supports the interpretation of clinical co-occurrences through plausible mechanistic links between overlapping disease pathways, offering high-resolution insights at both molecular and clinical levels. Availability and implementation: The BEL files, Neo4j database, and Cytoscape visualization files are publicly available at: https://github.com/SCAI-BIO/CBM-Comorbidity-KG .

10 March 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
FHFeng He
Feng He
AMAndrea Martí-Sarrias
Andrea Martí-Sarrias
HGHeval Atas Guvenilir
Heval Atas Guvenilir
RSRenata Vieira de Sá
Renata Vieira de Sá
ASAdithya Sridhar
Adithya Sridhar
RKRejko Krüger
Rejko Krüger
Background: Neurological complications are among typical clinical manifestations, both during the acute phase of SARS-CoV-2 infection and long-term post-acute COVID-19 sequelae, i.e., Long COVID. A growing body of evidence connects SARS-CoV-2 infection to systemic inflammation, peripheral immune dysregulation, blood-brain barrier (BBB) dysfunction, neuroinflammatory processes, mitochondrial dysfunction and pathological protein aggregation, all of which are central to the pathogenesis of major neurodegenerative diseases. Main Body: In this review, we discuss the converging shared underlying molecular mechanisms that link the ‘acute’ SARS-CoV-2 infection that often only lasts for days and ‘chronic’ neurodegenerative diseases that often take decades to develop. We further review human induced pluripotent stem cells (iPSCs)-derived brain organoid and BBB models for Parkinson’s disease (PD) and Alzheimer’s disease (AD) as well as artificial intelligence (AI)-facilitated knowledge graph methods that are used to hypothesize, discover and validate the potential mechanistic links. Conclusions: We suggest that besides the established links between viral infections and neurodegenerative or neuroinflammatory conditions, such as Epstein-Barr virus (EBV) in multiple sclerosis or herpes zoster in AD, SARS-CoV-2 infection is another important factor defining the future burden of the most common neurodegenerative diseases.

14 June 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
TDTunca Doğan
Tunca Doğan
EGEce Akhan Güzelcan
Ece Akhan Güzelcan
Marcus BaumannMarcus Baumann
Marcus Baumann
AKAltay Koyas
Altay Koyas
HAHeval Atas
Heval Atas
RCRengul Cetin-Atalay
Rengul Cetin-Atalay
Predictive approaches such as virtual screening have been used in drug discovery with the objective of reducing developmental time and costs. Current machine learning and network- based approaches have issues related to generalization, usability, or model interpretability, especially due to the complexity of target proteins’ structure/function, and bias in system training datasets. Here, we propose a new computational method “DRUIDom” to predict bio- interactions between drug candidate compounds and target proteins by utilizing the domain modularity of proteins, to overcome problems associated with current approaches. DRUIDom is composed of two methodological steps. First, ligands/compounds are statistically mapped to structural domains of their target proteins, with the aim of identifying physical or functional interactions. As such, other proteins containing the mapped domain or domain pair become new candidate targets for the corresponding compounds. Next, a million-scale dataset of small molecule compounds, including the ones mapped to domains in the previous step, are clustered based on their molecular similarities, and their domain associations are propagated to other compounds within the same clusters. Experimentally verified bioactivity data points, obtained from public databases, are meticulously filtered to construct datasets of active/interacting and inactive/non-interacting compound–target pairs (∼2.9M data points), and used as training data for calculating parameters of compound– domain mappings, which led to 27,032 high-confidence associations between 250 domains and 8,165 compounds, and a finalized output of ∼5 million new compound–protein interactions. DRUIDom is experimentally validated by syntheses and bioactivity analyses of compounds predicted to target LIM-kinase proteins, which play critical roles in the regulation of cell motility, cell cycle progression, and differentiation through actin filament dynamics. We showed that LIMK-inhibitor-2 and its derivatives significantly block the cancer cell migration through inhibition of LIMK phosphorylation and the downstream protein cofilin. One of the derivative compounds (LIMKi-2d) was identified as a promising candidate due to its action on resistant Mahlavu liver cancer cells. The results demonstrated that DRUIDom can be exploited to identify drug candidate compounds for intended targets and to predict new target proteins based on the defined compound–domain relationships. The datasets, results, and the source code of DRUIDom are fully-available at: https://github.com/cansyl/DRUIDom. Author Summary Drug development comprises several interlinked steps from designing drug candidate molecules to running clinical trials, with the aim to bring a new drug to market. A critical yet costly and labor-intensive stage is drug discovery, in which drug candidate molecules that specifically interact with the intended biomolecular target (mostly proteins) are identified. Lately, data-centric computational methods have been proposed to aid experimental procedures in drug discovery. These methods have the ability to rapidly assess large molecule libraries and reduce the time and cost of the process; however, most of them suffer from problems related to producing reliable biologically relevant results, preventing them from gaining real-world usage. Here, we have developed a new method called DRUIDom to predict unknown interactions between drugs/drug candidate compounds and biological targets by utilizing the modular structure of proteins. For this, we identify the domains, i.e., the evolutionary and functional building blocks of proteins, where these potential drug compounds can bind, and utilize this information along with protein domain annotations to predict new drug targets. We have tested the biological relevance of DRUIDom on selected proteins that play critical roles in the progression of numerous types of cancer. Cell-based experimental results indicated that predicted inhibitors are effective even on drug-resistant cancer cells. Our results suggest that DRUIDom produces novel and biologically relevant results that can be directly used in the early steps of the drug discovery process.